Tyrosine-modified recombinant rAAV vector compositions and methods for use
Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.
1. A recombinant adeno-associated viral (rAAV) vector that encodes a modified capsid protein, wherein the modified capsid protein comprises at least a first non-tyrosine amino acid at a position that corresponds to a surface-exposed tyrosine residue selected from the group consisting of Tyr252, Tyr272, Tyr275, Tyr281, Tyr508, Tyr612, Tyr704, Tyr720, Tyr730, and Tyr673 in the wild-type AAV2 capsid protein, and further wherein the transduction efficiency of a virion comprising the modified capsid protein is higher than that of a virion comprising a corresponding, unmodified wild-type AAV2 capsid protein.
2. The rAAV vector of claim 1 , wherein the surface-exposed tyrosine residue corresponds to Tyr252, Tyr272, Tyr704, or Tyr730 of a wild-type AAV2 capsid protein.
3. The rAAV vector of claim 1 , wherein the transduction efficiency of a virion comprising the modified capsid protein is about 4- to about 29-fold higher than that of a virion comprising a corresponding, unmodified, wild-type capsid protein.
4. The rAAV vector of claim 3 , wherein the transduction efficiency of a virion comprising the modified capsid protein is about 8- to about 11-fold higher than that of a virion comprising a corresponding, unmodified, wild-type capsid protein.
5. The rAAV vector of claim 1 , wherein the virion comprising the modified capsid protein is less susceptible to ubiquitination when introduced into a mammalian cell than that of a virion comprising a corresponding, unmodified, wild-type capsid protein.
6. The rAAV vector of claim 1 , wherein the at least a first non-tyrosine residue is a phenylalanine residue.
7. The rAAV vector of claim 1 , further comprising a polynucleotide that encodes at least a first therapeutic agent operably linked to a promoter capable of expressing the polynucleotide in a mammalian host cell that comprises the vector.
8. The rAAV vector of claim 7 , wherein the promoter comprises a heterologous, tissue-specific, constitutive or inducible promoter.
9. The rAAV vector of claim 7 , wherein the promoter comprises a mammalian or avian β-actin promoter.
10. The rAAV vector of claim 7 , wherein the polynucleotide further comprises a post-transcriptional regulatory sequence or a polyadenylation signal.
11. The rAAV vector of claim 7 , wherein the polynucleotide is operably linked to an enhancer sequence.
12. The rAAV vector of claim 7 , wherein the therapeutic agent is selected from the group consisting of a polypeptide, a peptide, an antibody, an antigen binding fragment, a ribozyme, a peptide nucleic acid, an siRNA, an RNAi, an antisense oligonucleotide and an antisense polynucleotide.
13. The rAAV vector of claim 1 , comprised within an adeno-associated viral particle or infectious rAAV virion.
14. The rAAV vector of claim 1 , comprised within an isolated mammalian host cell selected from the group consisting of a human, primate, murine, feline, canine, porcine, ovine, bovine, equine, epine, caprine and lupine host cell.
15. The rAAV vector of claim 14 , wherein the isolated mammalian host cell is an endothelial, epithelial, vascular, liver, lung, heart, pancreas, intestinal, kidney, muscle, bone, neural, blood, or brain cell.
16. A composition comprising: (a) a recombinant adeno-associated viral (rAAV) vector that encodes a modified capsid protein, wherein the modified capsid protein comprises at least a first non-tyrosine amino acid at a position that corresponds to a surface-exposed tyrosine residue selected from the group consisting of Tyr252, Tyr272, Tyr275, Tyr281, Tyr508, Tyr612, Tyr704, Tyr720, Tyr730, and Tyr673 in the wild-type AAV2 capsid protein, and further wherein the transduction efficiency of a virion comprising the modified capsid protein is higher than that of a virion comprising a corresponding, unmodified wild-type AAV2 capsid protein; and (b) a pharmaceutically-acceptable diluent, buffer, carrier, or excipient.
17. A diagnostic or therapeutic kit comprising the composition of claim 16 , and instructions for using the kit for diagnosing, preventing, treating or ameliorating one or more symptoms of a mammalian disease, injury, disorder, trauma or dysfunction in a mammal.
18. A recombinant adeno-associated viral (rAAV) vector that encodes a modified AAV2 capsid protein, wherein the modified AAV2 capsid protein comprises a substitution of one or more surface-exposed tyrosine residues selected from the group consisting of Tyr252, Tyr272, Tyr275, Tyr281, Tyr444, Tyr500, Tyr508, Tyr576, Tyr612, Tyr700, Tyr704, Tyr720, Tyr730, and Tyr673 in the wild-type AAV2 capsid protein with at least a first non-tyrosine amino acid, and further wherein the transduction efficiency of a virion comprising the modified AAV2 capsid protein is higher than that of a virion comprising the wild-type, un-substituted, AAV2 capsid protein.
19. A recombinant adeno-associated viral (rAAV) vector that encodes a modified capsid protein, wherein the modified capsid protein comprises a substitution of one or more surface-exposed tyrosine residues that correspond to Tyr252, Tyr272, Tyr275, Tyr281, Tyr508, Tyr612, Tyr704, Tyr720, Tyr730, or Tyr673 in a wild-type AAV2 capsid protein, with at least a first non-tyrosine amino acid, and further wherein the transduction efficiency of a virion comprising the modified capsid protein is higher than that of a virion comprising the wild-type, un-substituted, capsid protein.
20. A recombinant adeno-associated viral (rAAV) vector that encodes a modified capsid protein, wherein the modified capsid protein comprises a substitution of one or more surface-exposed tyrosine residues in the wild-type capsid protein with at least a first non-tyrosine amino acid, and further wherein the transduction efficiency of a virion comprising the modified capsid protein is higher than that of a virion comprising the wild-type, un-substituted, capsid protein, wherein the one or more surface-exposed tyrosine residues correspond to one or more of Tyr252, Tyr272, Tyr275, Tyr281, Tyr508, Tyr612, Tyr704, Tyr720, Tyr730, and Tyr673 of a wild-type, AAV2 capsid protein.